Should you build or buy Medication Safety & Adverse Drug Event Surveillance?

Medication safety and adverse drug event surveillance software monitors prescription orders, dispensing records, lab values, and clinical notes to detect potential medication errors, high-risk drug exposures, and adverse drug events before or after they reach the patient. It applies clinical pharmacology rules — Beers criteria, renal dosing adjustments, drug interaction databases — to flag outliers and route alerts to pharmacists or clinical safety teams.

Copy reviewed 2026-09-19 · Research revision 2026-09-06

Compare the full detection-to-reporting workflow with the narrower detector your clinical team could validate and maintain. Public rules and individual self-builds support investigation; they do not establish that replacing a surveillance platform will improve outcomes or reduce costs.

Build it, buy it, or bridge?

⚒ Build it
✓ Buy it
➔ Bridge
Cost shape
Clinical validation, data integration, alert operations, and maintenance must be budgeted
Subscription pricing; vendor maintains drug interaction databases and clinical rules as guidelines evolve
Buy ADE detection core; build population-specific detection models or reporting layers on top
Time to value
Depends on data readiness, detector scope, and clinical validation
Configuration, integration, and local clinical validation are required before use
Vendor baseline operational quickly; custom models layered in after initial deployment
Differentiation captured
Meaningful if detection models are tuned to your formulary and patient mix rather than generic vendor defaults
Standard drug safety coverage without differentiation; detection logic is evidence-based and generic
Custom population-level surveillance layered on vendor detection infrastructure
AI feasibility today
Narrow production examples exist; broad multi-hospital replacement evidence remains limited
Vendors incorporating ML-based anomaly detection; ongoing drug database maintenance remains vendor advantage
Internal ML models trained on owned EHR data alongside vendor alert management and dashboards
Who it fits
Large IDNs and academic health systems with clinical informatics teams and formulary-specific detection needs
Hospitals needing full detection-to-reporting workflow without internal clinical pharmacology informatics capacity
IDNs wanting custom detection models while using vendor alert management and cross-system reporting

When building makes sense

Consider a scoped build when clinical informatics staff can validate a detector for a defined population, formulary, or risk pattern. The research supports narrower examples, not a general claim that large health systems routinely replace the full surveillance platform. Owned EHR data and published clinical rules are inputs; local validation, alert routing, monitoring, and ongoing clinical ownership still have to be established.

When buying makes sense

Buying earns its keep when you need the full detection-to-reporting workflow, including integration, alert management, pharmacist routing, and maintained drug information. Your clinical team still needs to validate the system locally and monitor its performance. An internal detector can run alongside a purchased platform when it addresses a specific gap.

The desk read

Consider a scoped build when clinical informatics staff can validate a detector for a defined population, formulary, or risk pattern. The research supports narrower examples, not a general claim that large health systems routinely replace the full surveillance platform. Owned EHR data and published clinical rules are inputs; local validation, alert routing, monitoring, and ongoing clinical ownership still have to be established.

Buying earns its keep when you need the full detection-to-reporting workflow, including integration, alert management, pharmacist routing, and maintained drug information. Your clinical team still needs to validate the system locally and monitor its performance. An internal detector can run alongside a purchased platform when it addresses a specific gap.

Representative vendors MedAwareAB Cube SafetyEasyHealth Catalyst Patient Safety MonitorVigiLanz (Pharmacy/ADE module)Bainbridge Health + 10 more, listed in the full index

Vendors in Medication Safety & Adverse Drug Event Surveillance

Each file covers what the product is, its funding history, and when the index last verified it alive.

Frequently asked

What is Medication Safety & Adverse Drug Event Surveillance software?

Medication safety and adverse drug event surveillance software monitors prescription orders, dispensing records, lab values, and clinical notes to detect potential medication errors, high-risk drug exposures, and adverse drug events before or after they reach the patient. It applies clinical pharmacology rules — Beers criteria, renal dosing adjustments, drug interaction databases — to flag outliers and route alerts to pharmacists or clinical safety teams.

When does building Medication Safety & Adverse Drug Event Surveillance make sense?

Consider a scoped build when clinical informatics staff can validate a detector for a defined population, formulary, or risk pattern. The research supports narrower examples, not a general claim that large health systems routinely replace the full surveillance platform. Owned EHR data and published clinical rules are inputs; local validation, alert routing, monitoring, and ongoing clinical ownership still have to be established.

When does buying Medication Safety & Adverse Drug Event Surveillance make sense?

Buying earns its keep when you need the full detection-to-reporting workflow, including integration, alert management, pharmacist routing, and maintained drug information. Your clinical team still needs to validate the system locally and monitor its performance. An internal detector can run alongside a purchased platform when it addresses a specific gap.

What are the main Medication Safety & Adverse Drug Event Surveillance vendors?

Representative vendors include MedAware, AB Cube SafetyEasy, Health Catalyst Patient Safety Monitor, VigiLanz (Pharmacy/ADE module), Bainbridge Health. B4 Pro includes the category score and the full vendor list.

How is ADE surveillance different from the drug interaction checking built into most EHRs?

EHR-embedded drug interaction checking is point-of-prescribing — it fires at order entry. ADE surveillance runs continuously across all active medications, lab trends, and clinical notes, catching exposures that slip through at ordering (dose accumulation, renal function changes after the initial order, population-level outlier patterns). Dedicated surveillance platforms are also designed to minimize alert fatigue by applying smarter thresholds than EHR default checks, which are typically calibrated too broadly.

The B4 Index scores every software category on two axes, strategic differentiation and AI feasibility, to classify it Build, Buy, Bridge, or Beware. See the full methodology.